Last updated: February 24, 2026
What is the drug associated with NDC 70700-0146?
NDC 70700-0146 corresponds to SARS-CoV-2 Antigen Diagnostic Tests, specifically a rapid antigen test used for COVID-19 detection. It is produced by Abbott Laboratories under the BinaxNOW brand. This test detects nucleocapsid protein of SARS-CoV-2 through lateral flow immunoassay.
Market Landscape
Product Role and Indications
- Diagnostic Purpose: Used for point-of-care screening, especially in settings with high throughput like clinics, workplaces, travel hubs, and community testing sites.
- Regulatory Status: Granted Emergency Use Authorization (EUA) by the FDA, with subsequent full approvals or extensions depending on evolving public health policy.
Market Size
- Global Demand: Driven by ongoing COVID-19 surveillance, with estimated global COVID-19 testing volume exceeding 2 billion tests annually (as of 2022).
- U.S. Market Share: Abbott's BinaxNOW holds an estimated 60-70% of the rapid antigen test market within the U.S. (source: IQVIA, 2022).
Competitive Landscape
| Manufacturer |
Market Share |
Price Range (per test) |
Notes |
| Abbott (BinaxNOW) |
60-70% |
$5-$25 |
Widely available, FDA EUA |
| Quidel (QuickVue) |
10-15% |
$7-$20 |
Alternative rapid tests |
| Becton Dickinson |
5-10% |
$6-$15 |
Emerging market entries |
| Others |
5-15% |
$8-$30 |
Includes imports, local brands |
Distribution Channels
- Major pharmacies
- Grocery store chains
- Healthcare providers
- Direct partnerships with governments for mass testing
Price Trends and Projections
Historical Pricing
- Pre-2022: Retail testing kits sold at $15-$25 per test, reflecting supply chain costs, regulatory expenses, and limited competition.
- 2022-2023: Prices declined to $5-$10 per test due to increased manufacturing scale, supply chain stabilization, and generic entry.
Influencing Factors
- Manufacturing Capacity: Expansion increases supply, driving prices downward.
- Regulatory Changes: Evolving EUA policies and potential full approvals can affect pricing.
- Market Demand: Fluctuates with pandemic waves, vaccine coverage, and public health directives.
- Competitive Entry: New entrants or alternative testing methods can reduce prices.
Price Projection (Next 12 Months)
| Scenario |
Expected Price Range |
Key Drivers |
| Base Case |
$4-$8 per test |
Continued scale-up, stable demand, mature manufacturing |
| Optimistic |
$3-$6 per test |
High supply, reduced manufacturing costs, increased approvals |
| Pessimistic |
$6-$12 per test |
Supply chain disruptions, regulatory delays, demand contraction |
Market Factors Impacting Projections
- Global vaccination efforts decline demand in some regions, potentially stabilizing prices. Conversely, emerging variants and breakthrough cases may renew testing requirements.
- Government procurement programs continue to influence supply and pricing, especially in the U.S., with federal purchase agreements maintaining lower prices.
Regulatory and Policy Impact
- FDA EUA extensions for diagnostic tests sustain market confidence and demand.
- Potential full approvals could either normalize prices or allow for premium pricing based on approved indications.
- International regulations vary, influencing the pricing landscape outside North America.
Key Takeaways
- NDC 70700-0146 (BinaxNOW COVID-19 rapid antigen test) dominates rapid testing with over 60% U.S. market share.
- The market experienced a price decline from $15-$25 pre-2022 to $5-$10 currently.
- Future prices are expected to stabilize between $4-$8 per test, influenced by manufacturing capacity, demand, and regulatory policies.
- Market growth will largely depend on the trajectory of COVID-19 variants, vaccination rates, and public health testing mandates.
FAQs
1. What factors could increase the price of the BinaxNOW test?
Supply chain disruptions, regulatory delays, increased raw material costs, and a resurgence of COVID-19 cases could push prices higher.
2. How does the market share of Abbott compare to competitors?
Abbott's BinaxNOW holds around 60-70% of the U.S. rapid antigen test market, outpacing Quidel and others.
3. Are there regulatory barriers affecting future price trends?
Yes. Full FDA approval or new EUAs could alter market dynamics, influencing pricing strategies.
4. How does government procurement affect the retail price?
Mass procurement agreements typically lower retail prices due to bulk purchasing and negotiated discounts.
5. What is the outlook for international markets?
Pricing outside North America varies widely, impacted by local regulation, import tariffs, and regional demand. Some markets may see higher prices due to supply limitations.
References
[1] IQVIA. (2022). COVID-19 testing market share report.
[2] U.S. Food and Drug Administration. (2022). Emergency Use Authorization details for SARS-CoV-2 diagnostic tests.
[3] MarketWatch. (2023). COVID-19 rapid test market analysis.
